Prosecution Insights
Last updated: November 04, 2026
Application No. 18/024,928

COMBINATION COMPOSITIONS AND METHODS FOR TREATING CANCER

Final Rejection §103§112§DP
Filed
Mar 06, 2023
Priority
Sep 04, 2020 — provisional 63/074,968 +1 more
Examiner
LU, CHENG
Art Unit
1642
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Austral University
OA Round
2 (Final)
54%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
119 granted / 222 resolved
-6.4% vs TC avg
Strong +65% interview lift
Without
With
+64.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
56 currently pending
Career history
297
Total Applications
across all art units

Statute-Specific Performance

§101
2.6%
-37.4% vs TC avg
§103
30.2%
-9.8% vs TC avg
§102
13.1%
-26.9% vs TC avg
§112
32.4%
-7.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 222 resolved cases

Office Action

§103 §112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION The amendment filed May 26, 2025 in response to the Office Action of February 24, 2026 is acknowledged and has been entered. Claims 15, 17 and 21 have been amended. Claims 16, 18, and 19 have been cancelled. Claims 1-15, 17, 20-31 are pending. Claims 1-14 and 24-31 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventions or species, there being no allowable generic or linking claim. Claims 15, 17, and 20-23 are currently under consideration as drawn to the elected invention. In view of the claim amendments and Applicant’s arguments, the 112(a) rejection set forth in the previous Office Action of 02/24/2026 is hereby withdrawn. In view of the claim amendments (removal of option (d)), the 103 rejection set forth in the previous Office Action of 02/24/2026 is hereby withdrawn. In view of the claim amendments (removal of option (d)), the Double Patenting rejection set forth in the previous Office Action of 02/24/2026 is hereby withdrawn. As noted in previous Office Action of 02/24/2026, prior art does not teach an anti-cancer combination of ELV-N32 or ELV-N34 plus anti-VEGF antibody; ELV-N32 or ELV-N34 plus Suramab. However, the instant claims are not limited these combinations. Thus, new rejections are made below. Claim Objections Claim 15 is objected to because of the following informalities: “e. a therapeutically…” should be “d. a therapeutically …” because the original option d. has been removed. Appropriate correction is required. NEW REJECTION Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 20 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 20, which depends on claim 15, recites “wherein the compound of Formula I is: PNG media_image1.png 138 400 media_image1.png Greyscale ,… PNG media_image2.png 122 422 media_image2.png Greyscale ” However, claim 15 recites Formula I as: PNG media_image3.png 98 344 media_image3.png Greyscale wherein the m is 1-4; X is O or S; R1 is H or Cl; R3 is H or Cl; R2 is H, butoxy, or Cl; and wherein, when: R2 is butoxy, m is 1 or 4, or when R1 and R2 are both Cl, and X is O, m is 3 or 4. For LAU-0901, wherein R1 and R2 are both Cl, and X is O, but m is 2; for LAU-09017, R2 is butoxy, but m is 2. Thus, claim 20 fails to include all the limitations of claim 15 and broaden the scope of claim 15. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 15, 17, and 20-23 are rejected under 35 U.S.C. 103 as being unpatentable over Bazan (Bazan et al., WO 2016/144995, Publication Date: 09/15/2016, of record) in view of Garcia (Garcia et al., CANCER TREATMENT REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 86, Publication Date: 03/26/2020, cited in IDS of 08/16/2024, of record) and Lopez (Lopez et al., Cancer Chemother Pharmacol, 67: 723-728, Publication Date: 09/21/2010, cited in IDS of 08/16/2024). Bazan teaches compound of Formula (I), such as LAU-09015, LAU-0901 (the elected species) (claims 1, 2, 8 and 12). Bazan teaches a method of treating a brain tumor with a PAF-receptor antagonist of formula (I), such as LAU-0901, LAU-09015 (claims 7 and 8). Bazan teaches that the brain tumor can be a glioblastoma (claim 9), in particular GBM (Examples 6-9). Taken together, Bazan teaches an anti-cancer composition comprising a PAF-receptor antagonist of Formula (I), such as LAU-0901, or LAU-09015. It is noted that LAU-0901, or LAU-09015 reads on the instant claims 18-20. However, Bazan does not teach combination with Suramab. Garcia teaches VEGFs have been identified as key factors for inducing tumor angiogenesis. VEGF can stimulate the proliferation and survival of endothelial cells and increase the permeability of vessels, thereby supporting the metabolic demands (the bridging paragraph of pages 1-2). Garcia teaches an important role of VEGF in cancer progression was supported by the association of elevated intra-tumoral VEGF expression levels with poorer prognosis or more aggressive disease in several solid tumor types, including metastatic colorectal cancer (mCRC), non-small-cell lung cancer (NSCLC), metastatic breast cancer (mBC), glioblastoma multiforme (GBM) and ovarian cancer (OC) (page 2, col. 1, the bottom paragraph). Garcia teaches that bevacizumab can be used to treat GBM (page 10, col. 2), bevacizumab is an anti-VEGF antibody as evidenced by the instant claim 14. Garcia also teaches that ongoing research into combining bevacizumab with other treatments (Table 4) to enhance its efficacy (page 15, col. 1, para. 4). Lopez teaches suramab is a new pharmaceutical combination of two anti-angiogenic compounds, suramin and bevacizumab, which showed a high synergistic effect when administered jointly (Abstract). Lopez teaches A greater inhibitory effect was obtained with Suramab compared to that obtained with Bevacizumab. Suramab significantly reduced tumor volume and prolonged survival of mice compared to controls (Abstract, and Fig. 2). Lopez teaches that Suramab has a potent antiangiogenic effect because it inhibits not only VEGF (through Bevacizumab) but also other pro-angiogenic growth factors such as TGF-β, PDGF, bFGF, and postreceptor-inducible tyrosine phosphorylation of KDR (page 727, col. 1, para. 2). Lopez teaches that the concentration and dose of suramin and bevacizumab used in Suramab are much lower than those pointed out as toxic levels of suramin and bevacizumab. Accordingly, no significant side effects were seen with Suramab (page 727, col. 1, para. 2). Lopez teaches that Suramab could be employed in adjuvancy with chemotherapeutic agents for cancer therapy (page 727, col. 1, para. 3). It would have prima facie been obvious to one of ordinarily skilled in the art before the time the invention was filed to modify the method of treating a GBM with a PAF-receptor antagonist of formula (I), such as LAU-0901, LAU09015 as taught by Bazan and to combine LAU-0901 and Suramab, because Garcia teaches that bevacizumab is a well-known and standard compound for treating GBM and Lopez teaches that combination of bevacizumab and suramin (Suramab) shows synergistic anti-tumor effect. One of ordinary skill would have been motivated and have expected that combination with Suramab would enhance the efficacy of the treatment by combining multiple mode of actions. Because both components are well known in the art, one of ordinary skill would have been motivated and have reasonable expectation of success to make an anti-cancer composition comprising both components for a simpler application. Claim 17 is a limitation of the alternative elovanoid composition of claim 15, but it does not exclude the other alternative compositions such as option (e) of claim 15 from which it depends. Similarly, claim 21 is a limitation of the alternative anti-VEGF antibody composition of claim 15, but it does not exclude the option (e) of claim 15. Regarding claims 22 and 23, Bazan teaches pharmaceutical composition comprising a PAF-receptor antagonist and a pharmaceutically acceptable carrier and excipient, making the composition suitable for therapeutic use in vivo (page 13, para 3; the bridging paragraph of pages 15-16). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 15, 17, and 20-23 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 12,070,463 B2 (hereinafter Pat. 463) in view of Bazan (Bazan et al., WO 2016/144995, Publication Date: 09/15/2016, of record) and Garcia (Garcia et al., CANCER TREATMENT REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 86, Publication Date: 03/26/2020, cited in IDS of 08/16/2024, of record) and Lopez (Lopez et al., Cancer Chemother Pharmacol, 67: 723-728, Publication Date: 09/21/2010, cited in IDS of 08/16/2024). Claim 1 of Pat. 463 teaches a method for treating a seizure caused by a brain tumor, the method comprising the steps: (a) selecting a subject in need of treatment, wherein the subject has been diagnosed with a brain tumor; and (b) administering a therapeutic composition comprising a therapeutically effective amount of a platelet-activating factor (PAF) receptor antagonist and a pharmaceutically acceptable carrier, wherein the PAF receptor antagonist is: LAU-09015, LAU-09018, LAU-09021, LAU-09023, LAU-09025. These PAF-receptor antagonists read on the antagonists of instant claims 18-20. Claim 2 of Pat. 463 teaches that the brain tumor is selected from the group consisting of: a glioblastoma, an astrocytoma, an oligodendroglioma, an ependymal tumor, a neuronal tumor and a combination of glial tumors. Taken together, the claims of Pat. 463 teach using PAF-receptor antagonists (such as LAU-09015) in a pharmaceutical composition to treat brain tumor related conditions and a therapeutic composition comprising a PAF-receptor antagonist and a pharmaceutically acceptable carrier. However, the claims of Pat. 463 do not teach the combinations such as PAF-receptor antagonist + Suramab as instantly claimed. Bazan, Garcia, and Lopez’s teachings are described above. In particular, Bazan teaches Bazan teaches compound of Formula (I), such as LAU-09015, LAU-0901, LAU-09018, LAU-09021, LAU-09023, and LAU09025 (claim 11), and treating tumor cancers with these antagonists (claim 7). Bazan teaches that the brain tumor can be a glioblastoma (claim 9), in particular GBM (Examples 6-9). Garcia teaches that bevacizumab is the standard treatment for GBM (page 10, col. 2), bevacizumab is an anti-VEGF antibody as evidenced by the instant claim 14. Lopez teaches that Suramab is a new pharmaceutical combination of two anti-angiogenic compounds, suramin and bevacizumab, which showed a high synergistic effect when administered jointly It would have prima facie been obvious to one of ordinarily skilled in the art at the time the invention was filed to modify the method of treating a GBM with a PAF-receptor antagonist of formula (I), such as LAU-09015, LAU-0901, LAU-09018, LAU-09021, LAU-09023, or LAU09025 as taught by the claims of Pat. 463 and to combine these antagonists and Suramab as taught by Bazan, Garcia and Lopez, because both these PAF-receptor antagonists and Suramab are well-known and standard compound for treating GBM, as evidenced by Bazan, Garcia and Lopez. One of ordinary skill would have been motivated and have expected that combination would enhance the efficacy of the treatment by combining multiple modes of action for treating GBM. Because both components are well known in the art, one of ordinary skill would have been motivated and have reasonable expectation of success to make an anti-cancer composition comprising both components for a simpler application. Claim 17 is a limitation of the alternative elovanoid composition of claim 15, but it does not exclude the other alternative compositions such as option (e) of claim 15 from which it depends. Similarly, claim 21 is a limitation of the alternative anti-VEGF antibody composition of claim 15, but it does not exclude the option (e) of claim 15. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHENG LU whose telephone number is (571)272-0334. The examiner can normally be reached Monday-Friday 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571)270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHENG LU/ Examiner, Art Unit 1642 /SAMIRA J JEAN-LOUIS/Supervisory Patent Examiner, Art Unit 1642
Read full office action

Prosecution Timeline

Mar 06, 2023
Application Filed
Feb 24, 2026
Non-Final Rejection mailed — §103, §112, §DP
May 26, 2026
Response Filed
Aug 26, 2026
Final Rejection mailed — §103, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774471
ENGINEERED STREPTOMYCES ALBUS STRAINS
6y 0m to grant Granted Oct 27, 2026
Patent 12734202
ONCOLYTIC VIRUS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR FOR TREATING TUMORS
3y 10m to grant Granted Sep 15, 2026
Patent 12723080
MONOCLONAL ANTIBODY-CYTOKINE FUSION PROTEIN DIMER AND APPLICATION THEREOF
4y 8m to grant Granted Sep 01, 2026
Patent 12715921
ANTI-PD-1 ANTIBODIES FOR TREATMENT OF LUNG CANCER
2y 6m to grant Granted Aug 25, 2026
Patent 12692517
CRISPR/CAS12F ENZYME AND SYSTEM
5y 3m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
54%
Grant Probability
99%
With Interview (+64.8%)
3y 3m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 222 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month